---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-012904"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:43:04.794044+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Zevra CEO Richard Pascoe resigns effective June 1, 2023; two directors not standing for re-election

## Summary
- CEO Richard Pascoe resigned effective June 1, 2023; transition agreement provides 12 months base salary, pro-rated bonus, extended option exercise period.
- Directors Matthew Plooster and Joseph Saluri will not stand for re-election at 2024 annual meeting; will resign once board finds replacements.
- Board to immediately search for director candidates to fill the pending vacancies.

## SEC filing metadata
- accession: 0001437749-23-012904
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774923012904/0001437749-23-012904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774923012904/zvra20230507_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-012904
- JSON: https://secwatch.observer/filing/0001437749-23-012904.json
- Plain text: https://secwatch.observer/filing/0001437749-23-012904.txt

## Key facts
- Executive change
  Matthew R. Plooster departed as Director at ZEVRA THERAPEUTICS, INC..
  - Action: will not stand for re-election and will resign
  - Role: Director
  source text: on May 3, 2023, Matthew R. Plooster and Joseph B. Saluri, each a Class III director of the Company, notified the Company’s Board of Directors (the “Board”) that they do not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923012904/0001437749-23-012904-index.htm
- Executive change
  Richard W. Pascoe resigned as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On May 5, 2023, Richard W. Pascoe, the Chief Executive Officer of Zevra Therapeutics, Inc. (the “Company” or “Zevra”), resigned as the Company’s Chief Executive Officer, effective as of June 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923012904/0001437749-23-012904-index.htm
- Executive change
  Joseph B. Saluri departed as Director at ZEVRA THERAPEUTICS, INC..
  - Action: will not stand for re-election and will resign
  - Role: Director
  source text: on May 3, 2023, Matthew R. Plooster and Joseph B. Saluri, each a Class III director of the Company, notified the Company’s Board of Directors (the “Board”) that they do not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923012904/0001437749-23-012904-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.